Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cox

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
American Heart Journal|March 22, 2019
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) studyMatthew T Finn, Björn Redfors, Dimitri Karmpaliotis, et al.
Circulation|April 14, 2004
Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trialAlexandra J Lansky, Ricardo A Costa, Gary S Mintz, et al.
JACC. Cardiovascular Interventions|June 18, 2018
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES StudyGennaro Giustino, Björn Redfors, Ajay J Kirtane, et al.
The New England Journal of Medicine|November 25, 2006
Bivalirudin for patients with acute coronary syndromesGregg W Stone, Brent T McLaurin, David A Cox, et al.
The American Journal of Cardiology|May 2, 2016
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents StudyGennaro Giustino, Ajay J Kirtane, Usman Baber, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 14, 2019
Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudyGeoffrey A Rubin, Ajay J Kirtane, Shmuel Chen, et al.
The American Journal of Cardiology|July 30, 2017
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study)Björn Redfors, Ori Ben-Yehuda, Sheng-Hsuan Lin, et al.
International Journal of Cardiology|September 5, 2017
Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) studyGennaro Giustino, Björn Redfors, Roxana Mehran, et al.
JAMA|February 15, 2007
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trialGregg W Stone, Michel E Bertrand, Jeffrey W Moses, et al.
Circulation|October 12, 2005
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part IGregg W Stone, David E Kandzari, Roxana Mehran, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
American Heart Journal|March 22, 2019
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) studyMatthew T Finn, Björn Redfors, Dimitri Karmpaliotis, et al.
Circulation|April 14, 2004
Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trialAlexandra J Lansky, Ricardo A Costa, Gary S Mintz, et al.
JACC. Cardiovascular Interventions|June 18, 2018
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES StudyGennaro Giustino, Björn Redfors, Ajay J Kirtane, et al.
The New England Journal of Medicine|November 25, 2006
Bivalirudin for patients with acute coronary syndromesGregg W Stone, Brent T McLaurin, David A Cox, et al.
The American Journal of Cardiology|May 2, 2016
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents StudyGennaro Giustino, Ajay J Kirtane, Usman Baber, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 14, 2019
Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudyGeoffrey A Rubin, Ajay J Kirtane, Shmuel Chen, et al.
The American Journal of Cardiology|July 30, 2017
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study)Björn Redfors, Ori Ben-Yehuda, Sheng-Hsuan Lin, et al.
International Journal of Cardiology|September 5, 2017
Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) studyGennaro Giustino, Björn Redfors, Roxana Mehran, et al.
JAMA|February 15, 2007
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trialGregg W Stone, Michel E Bertrand, Jeffrey W Moses, et al.
Circulation|October 12, 2005
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part IGregg W Stone, David E Kandzari, Roxana Mehran, et al.
Pageof 17